MedKoo Cat#: 576319 | Name: IM-156 acetate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

IM156 is an oxidative phosphorylation inhibitor. IM156 is an orally bioavailable biguanide compound and mitochondrial oxidative phosphorylation (OxPhos) inhibitor, with potential antineoplastic activity. M156 significantly increased survival rate against caecal ligation and puncture (CLP)-induced sepsis. Mechanistically, IM156 markedly reduced viable bacterial burden in the peritoneal fluid and peripheral blood and attenuated organ damage in a CLP-induced sepsis model. IM156 also inhibited the apoptosis of splenocytes and the production of inflammatory cytokines including IL-1β, IL-6 and IL-10 in CLP mice. Moreover, IM156 strongly inhibited the generation of reactive oxygen species and subsequent formation of neutrophil extracellular traps in response to lipopolysaccharide in neutrophils.

Chemical Structure

IM-156 acetate
IM-156 acetate
CAS#1422365-94-3 (acetate)

Theoretical Analysis

MedKoo Cat#: 576319

Name: IM-156 acetate

CAS#: 1422365-94-3 (acetate)

Chemical Formula: C15H20F3N5O3

Exact Mass: 0.0000

Molecular Weight: 375.35

Elemental Analysis: C, 48.00; H, 5.37; F, 15.18; N, 18.66; O, 12.79

Price and Availability

Size Price Availability Quantity
10mg USD 350.00 2 Weeks
25mg USD 650.00 2 Weeks
50mg USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
1422365-52-3 (HCl) 1422365-93-2 (free base) 1422365-94-3 (acetate) 2043654-64-2 (TFA) 2043654-70-0 (malonate) 2043654-72-2 (furmate) 2043654-97-1 (tosylate) 2043654-98-2 (mesylate)
Synonym
HL-156A; HL156A; HL 156A; IM-156 acetate; IM 156 acetate; IM156 acetate
IUPAC/Chemical Name
N-(Imino((4-(trifluoromethoxy)phenyl)amino)methyl)-1-pyrrolidinecarboximidamide, acetate
InChi Key
AGFDCTOLSXWRDZ-UHFFFAOYSA-N
InChi Code
1S/C13H16F3N5O.C2H4O2/c14-13(15,16)22-10-5-3-9(4-6-10)19-11(17)20-12(18)21-7-1-2-8-21;1-2(3)4/h3-6H,1-2,7-8H2,(H4,17,18,19,20);1H3,(H,3,4)
SMILES Code
CC(=O)O.FC(F)(F)Oc1ccc(NC(=N)NC(=N)N2CCCC2)cc1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 375.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Shim JS, Kim EJ, Lee LE, Kim JY, Cho Y, Kim H, Kim J, Jang SH, Son J, Cheong JH, Kim A, Lim BJ, Ha SJ, Song JJ, Kim BS. The oxidative phosphorylation inhibitor IM156 suppresses B-cell activation by regulating mitochondrial membrane potential and contributes to the mitigation of systemic lupus erythematosus. Kidney Int. 2023 Feb;103(2):343-356. doi: 10.1016/j.kint.2022.09.031. Epub 2022 Nov 1. PMID: 36332729. 2: Janku F, Beom SH, Moon YW, Kim TW, Shin YG, Yim DS, Kim GM, Kim HS, Kim SY, Cheong JH, Lee YW, Geiger B, Yoo S, Thurston A, Welsch D, Rudoltz MS, Rha SY. First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2022 Oct;40(5):1001-1010. doi: 10.1007/s10637-022-01277-9. Epub 2022 Jul 8. PMID: 35802288; PMCID: PMC9395488. 3: Kang JH, Lee SK, Yun NJ, Kim YS, Song JJ, Bae YS. IM156, a new AMPK activator, protects against polymicrobial sepsis. J Cell Mol Med. 2022 Jun;26(12):3378-3386. doi: 10.1111/jcmm.17341. Epub 2022 May 2. PMID: 35502484; PMCID: PMC9189331. 4: Willette RN, Mangrolia P, Pondell SM, Lee CYW, Yoo S, Rudoltz MS, Cowen BR, Welsch DJ. Modulation of Oxidative Phosphorylation with IM156 Attenuates Mitochondrial Metabolic Reprogramming and Inhibits Pulmonary Fibrosis. J Pharmacol Exp Ther. 2021 Nov;379(3):290-300. doi: 10.1124/jpet.121.000811. Epub 2021 Sep 30. PMID: 34593558. 5: Izreig S, Gariepy A, Kaymak I, Bridges HR, Donayo AO, Bridon G, DeCamp LM, Kitchen-Goosen SM, Avizonis D, Sheldon RD, Laister RC, Minden MD, Johnson NA, Duchaine TF, Rudoltz MS, Yoo S, Pollak MN, Williams KS, Jones RG. Repression of LKB1 by miR-17∼92 Sensitizes MYC-Dependent Lymphoma to Biguanide Treatment. Cell Rep Med. 2020 May 19;1(2):100014. doi: 10.1016/j.xcrm.2020.100014. PMID: 32478334; PMCID: PMC7249503. 6: Son J, Cho YW, Woo YJ, Baek YA, Kim EJ, Cho Y, Kim JY, Kim BS, Song JJ, Ha SJ. Metabolic Reprogramming by the Excessive AMPK Activation Exacerbates Antigen-Specific Memory CD8+ T Cell Differentiation after Acute Lymphocytic Choriomeningitis Virus Infection. Immune Netw. 2019 Mar 5;19(2):e11. doi: 10.4110/in.2019.19.e11. PMID: 31089438; PMCID: PMC6494768.